236 related articles for article (PubMed ID: 15086599)
1. Does sequencing the PKRBD of hepatitis C virus NS5A predict therapeutic response to combination therapy in an Australian population?
Macquillan GC; Niu X; Speers D; English S; Garas G; Harnett GB; Reed WD; Allan JE; Jeffrey GP
J Gastroenterol Hepatol; 2004 May; 19(5):551-7. PubMed ID: 15086599
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment.
Muñoz de Rueda P; Fuentes Rodríguez JM; Quiles Pérez R; Gila Medina A; Martín Álvarez AB; Casado Ruíz J; Ruíz Extremera A; Salmerón J
World J Gastroenterol; 2017 Jul; 23(25):4538-4547. PubMed ID: 28740342
[TBL] [Abstract][Full Text] [Related]
3. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin.
Hung CH; Lee CM; Lu SN; Lee JF; Wang JH; Tung HD; Chen TM; Hu TH; Chen WJ; Changchien CS
J Viral Hepat; 2003 Mar; 10(2):87-94. PubMed ID: 12614464
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.
Hayashi K; Katano Y; Kuzuya T; Tachi Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Urano F; Yoshioka K; Toyoda H; Kumada T; Goto H
J Med Virol; 2012 Mar; 84(3):438-44. PubMed ID: 22246829
[TBL] [Abstract][Full Text] [Related]
5. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection.
Murphy MD; Rosen HR; Marousek GI; Chou S
Dig Dis Sci; 2002 Jun; 47(6):1195-205. PubMed ID: 12064791
[TBL] [Abstract][Full Text] [Related]
6. NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: Correlation with the response to the combined interferon/ribavirin therapy.
Bouzgarrou N; Hassen E; Mahfoudh W; Gabbouj S; Schvoerer E; Ben Yahia A; Ben Mami N; Triki H; Chouchane L
J Med Virol; 2009 Dec; 81(12):2021-8. PubMed ID: 19856481
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients.
Bolcic F; Laufer N; Torres C; Cassino L; Reynoso R; Quarleri J
Antiviral Res; 2012 Aug; 95(2):72-81. PubMed ID: 22683884
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy.
Mori N; Imamura M; Kawakami Y; Saneto H; Kawaoka T; Takaki S; Aikata H; Takahashi S; Chayama K;
J Med Virol; 2009 Apr; 81(4):640-9. PubMed ID: 19235866
[TBL] [Abstract][Full Text] [Related]
9. Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations.
Pawlotsky JM; Germanidis G; Neumann AU; Pellerin M; Frainais PO; Dhumeaux D
J Virol; 1998 Apr; 72(4):2795-805. PubMed ID: 9525599
[TBL] [Abstract][Full Text] [Related]
10. Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin.
Sede M; Laufer N; Ojeda D; Gun A; Cahn P; Quarleri J
Arch Virol; 2013 Sep; 158(9):1907-15. PubMed ID: 23553458
[TBL] [Abstract][Full Text] [Related]
11. High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected with HCV genotype 1b.
Toyoda H; Kumada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Tada T; Arakawa T; Fujimori M; Niinomi T; Ando N; Yasuda S; Sakai K; Kimura J
J Gastroenterol; 2011 Apr; 46(4):501-9. PubMed ID: 20927636
[TBL] [Abstract][Full Text] [Related]
12. Mutations in two PKR-binding domains in chronic hepatitis C of genotype 3a and correlation with viral loads and interferon responsiveness.
Yokozaki S; Katano Y; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Goto H
J Med Virol; 2011 Oct; 83(10):1727-32. PubMed ID: 21837788
[TBL] [Abstract][Full Text] [Related]
13. Mutations in ISDR of NS5A gene influence interferon efficacy in Chinese patients with chronic hepatitis C virus genotype 1b infection.
Shen C; Hu T; Shen L; Gao L; Xie W; Zhang J
J Gastroenterol Hepatol; 2007 Nov; 22(11):1898-903. PubMed ID: 17914967
[TBL] [Abstract][Full Text] [Related]
14. Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy.
Veillon P; Payan C; Le Guillou-Guillemette H; Gaudy C; Lunel F
World J Gastroenterol; 2007 Feb; 13(8):1195-203. PubMed ID: 17451199
[TBL] [Abstract][Full Text] [Related]
15. Reappraisal of the importance of mutations in the NS5A-PKR-binding domain of hepatitis C-1b virus in the era of optimally individualized therapy.
Chen TM; Huang PT; Wen CF; Tung JN; Chow KC; Chen YP
J Viral Hepat; 2011 Feb; 18(2):119-28. PubMed ID: 20236237
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy.
Hayashi K; Katano Y; Ishigami M; Itoh A; Hirooka Y; Nakano I; Urano F; Yoshioka K; Toyoda H; Kumada T; Goto H
J Viral Hepat; 2011 Apr; 18(4):280-6. PubMed ID: 20367792
[TBL] [Abstract][Full Text] [Related]
17. Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses.
Muñoz de Rueda P; Casado J; Patón R; Quintero D; Palacios A; Gila A; Quiles R; León J; Ruiz-Extremera A; Salmerón J
J Virol; 2008 Jul; 82(13):6644-53. PubMed ID: 18448540
[TBL] [Abstract][Full Text] [Related]
18. Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy.
Hayashi K; Katano Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Yoshioka K; Toyoda H; Kumada T; Goto H
Liver Int; 2011 Oct; 31(9):1359-65. PubMed ID: 21745312
[TBL] [Abstract][Full Text] [Related]
19. Sequencing of E2 and NS5A regions of HCV genotype 3a in Brazilian patients with chronic hepatitis.
Malta Fde M; Medeiros-Filho JE; Azevedo RS; Gonçalves L; Silva LC; Carrilho FJ; Pinho JR
Mem Inst Oswaldo Cruz; 2010 Feb; 105(1):92-8. PubMed ID: 20209336
[TBL] [Abstract][Full Text] [Related]
20. Mutations in the NS5A gene of hepatitis C virus subtype 1b and response to peg-IFNα-2a/RBV combination therapy in Azerbaijani patients.
Bokharaei-Salim F; Keyvani H; Salehi-Vaziri M; Sadeghi F; Monavari SH; Mehrnoush L; Alavian SM
Arch Virol; 2014 Nov; 159(11):2893-9. PubMed ID: 25139545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
